Mode
Text Size
Log in / Sign up
Phase 4 N=28 Randomized Basic Science

Examining the Impact of Tampon Use on the Vaginal Microbiota

Vaginal Microbiota

Enrolled (actual)
28
Serious AEs
0.0%
Results posted
Jul 2018
Primary outcome: Primary: Change in Relative Abundance of Lactobacillus Species — .0084; -.0014; -.00004; .0104 relative abundance

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Tampon A (Device); Tampon B (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
University of Michigan
Primary completion
Sep 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Relative Abundance of Lactobacillus Species
.0084; -.0014; -.00004; .0104; -.0350; .0238
SECONDARY
Change in Relative Abundance of Gardnerella Vaginalis
.000046; 0; -.000045; 0; -.000045; 0

Summary

The vaginal microbiota is the community of bacteria in the vagina. The composition of the vaginal microbiota (which bacteria are present and how many of each are present) is known to affect vaginal health and contribute to the development of bacterial vaginosis (the largest cause of vaginal discharge and malodor, and the most common vaginal disorder). It is also known that the composition of the vaginal microbiota changes across a menstrual cycle with the largest changes happening during a woman's period. However, it is not know how tampon use affects vaginal microbiota composition. This study is being done to learn what effect tampon use has on vaginal microbiota composition during a woman's period and between periods.

Eligibility Criteria

Inclusion Criteria

  • regular menstrual cycles lasting 21-35 days
  • menses lasting for at least 4 days
  • current tampon user
  • good self-reported general health
  • good self-reported vaginal health

Exclusion Criteria

  • currently pregnant
  • planning to become pregnant in 4 months following enrollment
  • difficulty using tampons
  • current toxic shock syndrome
  • history of toxic shock syndrome
  • current sexually transmitted infection
  • current urinary tract infection
  • currently using antibiotics
  • antibiotic use in 4 weeks prior to enrollment
  • current antifungal use
  • antifungal use in 4 weeks prior to enrollment
  • autoimmune condition
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03346759). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search